RT Journal Article
SR Electronic
T1 A simple, sensitive and quantitative FACS-based test for SARS-CoV-2 serology in humans and animals
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.06.21262027
DO 10.1101/2021.09.06.21262027
A1 Ribes, Agnès Maurel
A1 Bessière, Pierre
A1 Guéry, Jean Charles
A1 Featherstone, Eloïse Joly
A1 Bruel, Timothée
A1 Robinot, Remy
A1 Schwartz, Olivier
A1 Abravanel, Florence
A1 Izopet, Jacques
A1 Joly, Etienne
YR 2021
UL http://medrxiv.org/content/early/2021/09/13/2021.09.06.21262027.abstract
AB Serological tests are important for understanding the physiopathology and following the evolution of the Covid-19 pandemic. Assays based on flow cytometry (FACS) of tissue culture cells expressing the spike (S) protein of SARS-CoV-2 have repeatedly proven to perform slightly better than the plate-based assays ELISA and CLIA (chemiluminescent immuno-assay), and markedly better than lateral flow immuno-assays (LFIA).Here, we describe an optimized and very simple FACS assay based on staining a mix of two Jurkat cell lines, expressing either high levels of the S protein (Jurkat-S) or the mCherry fluorescent protein (Jurkat-R, which serve as an internal negative control). We show that this Jurkat-S&R-flow test has a much broader dynamic range than a commercial ELISA test and performs at least as well in terms of sensitivity and specificity. Also, it is more sensitive and quantitative than the hemagglutination-based test HAT, which we described recently. The Jurkat-R&S-flow test requires only a few microliters of blood; thus, it can be used to quantify various Ig isotypes in capillary blood collected from a finger prick. It can be used also to evaluate serological responses in mice, cats and dogs. FACS tests offer a very attractive solution for laboratories with access to tissue culture and flow cytometry who want to monitor serological responses in humans or in animals, and how these relate to susceptibility to infection, or re-infection, by the virus, and to protection against Covid-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe first part of this project was funded by a private donation. The second part was funded by the ANR grant HAT-field to EJ. EJ is employed by INSERM.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All sera from the first cohort, and whole blood samples from the second cohort, were obtained from the Toulouse hospital, where all patients give, by default, their consent for any biological material left over to be used for research purposes after all the clinical tests requested by doctors have been duly completed. Material transfer was done under a signed agreement (CNRS n 227232, CHU n 20 427 C). This study was declared and approved by the governing body of the Toulouse University Hospital with the agreement number RnIPH 2021-99, confirming that ethical requirements were fully respected. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used for generating the figures are included as supplementary material. All other data can be obtained by request from the corresponding author.